A 49-year-old African American woman with no significant medical history came to the clinic because of abnormal retinal findings and mildly decreased visual acuity. She was told about these same findings 10 years ago but did not have a repeated eye examination until recently by another retina specialist. She reported no family history of retinal diseases. She initially received anti–vascular endothelial growth factor (VEGF) treatment, but was later referred because of a concern about either the idiopathic or paraneoplastic variant of acute exudative polymorphous vitelliform maculopathy (AEPVM). Initial workup by her primary care physician was unremarkable for malignancy. Her best-corrected visual acuity (BCVA) was 20/60 OD and 20/50 OS. An anterior segment examination was normal. Dilated fundus examination revealed multiple vitelliform lesions involving the macula and superior macula bilaterally (Figure 1). Fluorescein angiography revealed staining of these lesions with a pseudohypopyon appearance of the central vitelliform lesion in the left eye. Optical coherence tomography (OCT) showed hyperreflectance corresponding to the yellow pigment in the vitelliform lesions in the subretinal space. No evidence of a choroidal neovascular membrane was present on examination or imaging.
Please finish quiz first before checking answer.
Read the answer below and download your certificate.
Read the discussion below and retake the quiz.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Albert L. Lin, MD, Department of Ophthalmology, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216 (firstname.lastname@example.org).
Published Online: February 3, 2022. doi:10.1001/jamaophthalmol.2021.4983
Conflict of Interest Disclosures: Dr Lin reported advisory board consulting fees of $1800 from Allergan about dexamethasone intravitreal implant (Ozurdex) outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.